These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 35774427)
1. Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial. Liu B; Chen N; Zhao J; Yin A; Wu X; Xing C; Jiang G; Fu J; Wang M; Wang R; Niu J; Fu P; Ni Z; Hou F; Zhao J; Chen J; Chen Y; Shi W; Chen J; Li W; Xu G; Zhong L; Liu W; Ding G; Kondo Y; Yue C; Mei C Chronic Dis Transl Med; 2022 Jun; 8(2):134-144. PubMed ID: 35774427 [TBL] [Abstract][Full Text] [Related]
2. Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail. Chen N; Xing C; Niu J; Liu B; Fu J; Zhao J; Ni Z; Wang M; Liu W; Zhao J; Zhong L; Wu X; Li W; Chen Y; Shi W; Chen J; Yin A; Fu P; Wang R; Jiang G; Hou F; Ding G; Chen J; Xu G; Kondo Y; Su Y; Mei C Chronic Dis Transl Med; 2022 Mar; 8(1):59-70. PubMed ID: 35620165 [TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393 [TBL] [Abstract][Full Text] [Related]
5. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693 [TBL] [Abstract][Full Text] [Related]
6. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Provenzano R; Bhaduri S; Singh AK; Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787 [TBL] [Abstract][Full Text] [Related]
7. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333 [TBL] [Abstract][Full Text] [Related]
8. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629 [TBL] [Abstract][Full Text] [Related]
9. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification. Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD. Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481 [TBL] [Abstract][Full Text] [Related]
11. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study. Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa]. Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958 [TBL] [Abstract][Full Text] [Related]
15. Darbepoetin versus epoetin alfa for the correction of anemia in cancer patients receiving radiotherapy or chemoradiotherapy treatment. Ots PM; Carrizosa CL; Pérez AR; de Dios Saez Garrido J; Pérez JM Clin Med Oncol; 2008; 2():393-9. PubMed ID: 21892305 [TBL] [Abstract][Full Text] [Related]
16. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Patel M; Thimons DG; Winston JL; Langholff W; McGowan T J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214 [TBL] [Abstract][Full Text] [Related]
17. Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients. Bristoyiannis G; Germanos N; Grekas D; Hatzidimitriou C; Iatrou C; Memmos D; Moutafis S; Papachristoforou K; Papadoniou A; Pappas M; Sakellariou GA; Siamopoulos KC; Sombolos K; Stamatelou K; Stathakis CP; Stavgiannoudakis G; Stratigis S; Syrganis C; Tsakiris D; Valis D; Vlahojannis JG; Vlassopoulos D Curr Ther Res Clin Exp; 2005 May; 66(3):195-211. PubMed ID: 24672123 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study. Kim Y; Park SK; Cho WY; Joo KW; Shin SK; Kim DJ; Kim YL; Son SH; Chung W; Lee KY; Park SK; Kim JK; Kim SW; Kang DH; Kim JK; Jeon JS; Lee KW; Lee CH; Oh DJ; An WS; Lee JS; Kang GW; Do JY; Lee JP; Jin K BioDrugs; 2020 Feb; 34(1):99-110. PubMed ID: 31749113 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804 [TBL] [Abstract][Full Text] [Related]
20. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]